Eupraxia Pharmaceuticals Inc. EPRX
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Each USD of equity lost 67 cents this year.
The 4-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | ◌ |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −1.03 | −0.76 | −1.17 | −0.96 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — |
| ROE % | −66.8 | −143.2 | −564.3 | −237.5 |
| Shares out B | 0.05 | 0.04 | 0.03 | 0.02 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 3 of the 4 fiscal years we could check. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 30 checks were skipped: the balance sheet is not tagged before 2022. 15 checks were skipped: EPS is not tagged before 2022.